Cipla gets USFDA approval for combination AIDS drug

26 Sep 2011 Evaluate

Cipla, India’s second-largest pharma company has reportedly received tentative approval from the US Food and Drug Administration (USFDA) for its combination acquired immune deficiency syndrome (AIDS) drug containing lamivudine and zidovudine.

Recently, the company shut two of its four marketing divisions to improve its distribution. These two divisions, Protec and Omnicare, sold generic products and generate revenue about worth Rs 500 crore. The staff from these divisions will be accommodated in other areas of the company.

Cipla manufactures drugs to treat cardiovascular disease, arthritis, diabetes, weight control, depression and many other health conditions. Its products are distributed in more than 180 countries worldwide. The Mumbai-based firm which enjoys the highest share in India's pharmaceuticals market is known for selling low-cost generic versions of anti-retroviral drugs used to fight HIV/AIDS.

Cipla Share Price

1520.55 -0.65 (-0.04%)
05-Dec-2025 15:55 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1805.00
Dr. Reddys Lab 1276.55
Cipla 1520.55
Zydus Lifesciences 933.10
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×